We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Oncolytics Biotech Inc (ONC) Com NPV

Sell:1.16 CAD Buy:1.29 CAD Change: 0.12 CAD (9.16%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:1.16 CAD
Buy:1.29 CAD
Change: 0.12 CAD (9.16%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:1.16 CAD
Buy:1.29 CAD
Change: 0.12 CAD (9.16%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Contact details

Address:
1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
CALGARY
T2R 0C5
Canada
Telephone:
+1 (403) 6707377
Website:
https://www.oncolyticsbiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ONC
ISIN:
CA6823108759
Market cap:
84.78 million CAD
Shares in issue:
77.07 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Wayne Pisano
    Chairman of the Board, Interim Chief Executive Officer
  • Kirk Look
    Chief Financial Officer
  • Andrew Guttadauro
    Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.
  • Allison Hagerman
    Vice President - Product Development
  • Thomas Heineman
    Chief Medical Officer of Oncolytics Biotech (U.S.)

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.